Ergosterol peroxide (EPO, 1) is a major antitumor sterol produced by edible or medicinal mushrooms. Following oral administration of 1 to rats or anaerobic in vitro incubation of 1 with rat fecal bacteria, three metabolites were detected and their structures were identified to be 5a a,6a a-epoxyergosta-8(14),22-diene-3b b,7a a-diol (M1, 2), 5a a,6a a-epoxyergosta-8,22-diene-3b b,7a a-diol (M2, 3) , and 5a a,6a a-epoxy-3b b-hydroxyergosta-22-ene-7-one (M3, 4) by spectroscopic analysis. Of these, M2 and M3 showed more potent inhibitory activity than the original compound 1 against proliferation of CACO-2, WiDr, DLD-1 and Colo320 human colorectal adenocarcinoma cells. These findings suggest that bacterial metabolites of EPO play a significant role in its cytotoxic activity against human colorectal cancer cells.
Ergosterol peroxide (EPO, 1) is a steroid of the oxysterol type. It occurs widely in various mushroom species, yeast, lichens and spongies. 1, 2) It was reported that it could be prepared by conversion of ergosterol with a slow stream of oxygen under light and in the presence of a photosensitizing substance.
3) It is also a presumed product in the H 2 O 2 -dependent enzymatic oxidation of ergosterol. 4) EPO has significant cytotoxic activity. [5] [6] [7] [8] Recent pharmacological studies have demonstrated that EPO also possesses immunosuppressive, 9) human T lymphocyte inhibitory, 10) anti-inflammatory, 11) phospholipase A 2 inhibitory, anti-atherosclerosis 12) apoptosis-inducing, 13) DNA topoisomerase inhibitory, 14, 15) anticomplementary, 16) anti-viral, 17) anti-mycobacterial, 18) antibacterial, 19) sulfatase inhibitory, 20) and aldose reductase inhibitory 21) effects. Various mushrooms have been used as traditional or folk medicines for a long time. Phellinus linteus (BERK. and CUR-TIS) TENG., which belongs to the Hymenochaetceae in the Basidiomycetes, commonly referred to as Sanghwang in Korea, has been used as a medicinal mushroom for the treatment of inflammatory diseases and cancer in traditional Oriental medicine. Despite such great medicinal value, the supply of this medicinal mushroom is far from sufficient due to the high production costs and difficult growing techniques. To alleviate this situation, our group has developed a method for growing P. linteus on germinated brown rice (PB). Brown rice itself is known to contain rich nutrients 22) and arabinoxylan, which increases interferon gamma (IFN-g) secretion and activates NK cells. 23, 24) Since P. linteus is known to be rich in polysaccharides, previous studies on its activities were mostly focused on its polysaccharides and their anti-tumor effects. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Recently, several aromatic compounds such as p-hydroxybenzaldehyde, caffeic acid and hispidin have been isolated from cultured mycelia. 36) In the present investigation, we isolated EPO as a major low molecular constituent of PB.
Most of the ergosterol orally administered has been shown to be excreted in the feces in rats without absorption through the intestine. 37) Kobori et al. suggested that orally administered EPO in edible mushrooms might have a protective effect against colon cancer, and reported it possesses a suppressive effect against HT-29, CACO-2 human colorectal cancer cell lines, including the action mechanism.
11) However, until now, there have been no reports on the biotransformation of EPO by intestinal bacteria or the bioactivity of the metabolites. Here, we have examined the biotransformation of EPO by rat intestinal flora, and discuss the cytotoxic effect of the metabolites on four human colorectal adenocarcinoma cells (CACO-2, WiDr, DLD-1 and Colo-320) in comparison with EPO.
MATERIALS AND METHODS

Materials
Phellinus linteus grown on germinated brown rice (PB) was provided by Cell Activation Research Institute (CARI, Korea). These commercial preparations were made by the original method, as described previously.
38)
General An EAN-140 (Tabai Co., Osaka, Japan) anaerobic incubator was used for anaerobic incubation of samples with intestinal bacteria. The HPLC instrument was an Agilent 1100 system (Agilent Technologies, Waldbronn, Germany) consisting of an Agilent 1100 series binary pump with a photodiode array detector and a series 7725i injector with a 20 ml loop. Data were acquired and integrated using a Chemstation. The HPLC system was connected to an Esquire 3000 plus mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany) equipped with an atmospheric pressure chemical ionization (APCI) source. All LC/MS data were acquired using Esquire Control software and analyzed using software from Bruker Daltonik. Animals Specific pathogen-free male Wistar rats (8-week-old) were purchased from Japan SLS (Sankyo Laboratory Service, Tokyo, Japan). The Guidelines for Animal Experimentation, approved by the University of Toyama, were followed in these experiments.
Analytical Conditions of LC/MS HPLC separation was performed on a COSMOSIL 5C 18 -MS-II Waters column (particle size, 5 mm; 4.6ϫ150 mm i.d.) (Nacalai Tesque, Kyoto, Japan). The mobile phase contained a gradient of water and MeOH (0 min, 1 : 1, 10 min, 1 : 9, 28 min, 1 : 9 (v/v)) at a flow rate of 1 ml/min at 35°C. The flow rate was reduced by a splitter to 0.2 ml/min for the MS detection. The standard positive ion mode was selected for measurement under the following conditions: full scan range, m/z 50 to 950; nebulizer, 50 psi; dry gas, 10.0 l/min; and dry temperature, 360°C, APCI-temperature, 450°C. Analysis mode was full scan acquisition resulting in a typical total ion current (TIC) plot.
Isolation of EPO from PB Ergosterol peroxide was isolated from the PB as follows. The mycelia of PB (4 kg) were extracted three times with MeOH by soaking for 3 d. The combined solutions were evaporated under reduced pressure to yield a residue. The residue was suspended in H 2 O and extracted with ethyl acetate. The ethyl acetate fraction (50 g) was chromatographed on silica gel (10 cmϫ60 cm) and eluted consecutively with chloroform, 2% MeOH in chloroform, 5% MeOH in chloroform, 10% MeOH in chloroform, and 50% MeOH in chloroform. The 2% MeOH in chloroform fraction was chromatographed on silica gel (4.5 cmϫ50 cm) and RP-18 (3 cmϫ60 cm) to afford EPO (260 mg). (10 g) (Wako Pure Chemical Industry, twice recrystallized from 95% ethanol) and methylene blue (1 g) (Sigma-Aldrich, St. Louis, U.S.A.) were dissolved in 1 l of dichloromethane and placed in 50 ml test tubes. The solution was vigorously stirred by bubbling oxygen gas and irradiated with a 400 W high-pressure mercury lamp placed 10 cm away from the tubes. Water was circulated over the test tubes to maintain the reaction at room temperature. The reaction was monitored by TLC and stopped after 2 h. The crude reaction mixture was concentrated under reduced pressure to yield a residue, which was applied to a silica gel column eluted with 7% ethyl acetate in chloroform to afford EPO in 30% yield as a white solid.
Synthesis of EPO for the Isolation of Intestinal Bacterial Metabolites Ergosterol
1 H-and 13 C-NMR and EI-MS spectra were identical to those of EPO isolated from the mycelia of PB.
Preparation of Bacterial Mixture of Rat Feces Fresh feces (5 g), obtained from male Wistar strain rats (8 weeks old, Sankyo Laboratory Service, Tokyo, Japan), was homogenized in 100 ml of GAM broth and the sediments were removed by cotton gauze to give a 5% rat intestinal bacterial (RIB) mixture.
Preparation of Bacterial Mixture of Human Feces Fresh feces (5 g), obtained from a healthy subject, was homogenized in 100 ml of GAM broth and the sediments were removed by cotton gauze to give a 5% human intestinal bacterial (HIB) mixture.
LC-MS Analysis for the Transformation of EPO by RIB or HIB Fifty microliters of 100 mM EPO in MeOH and 500 ml of an RIB or HIB mixture were added to 4.45 ml of GAM broth, and the mixture was incubated at 37°C under anaerobic conditions. A 200 ml aliquot was removed at intervals and extracted with ethyl acetate. After evaporation of ethyl acetate with nitrogen gas, the residue was dissolved in 0.5 ml of MeOH. The MeOH solution was filtered through a 0.45 mm membrane filter, and a 10 ml portion was injected into a column for LC-MS analysis.
Incubation of EPO with an RIB Mixture and Isolation of Metabolites An RIB mixture (25 ml) and EPO (100 mg) in 1.5 ml of MeOH were added to 250 ml of GAM broth and anaerobically incubated at 37°C for 24 h. The reaction mixture was extracted three times with 300 ml of ethyl acetate. After evaporation of ethyl acetate in vacuo, the residue was applied to a column (3 cmϫ50 cm) of reversed phase-18 and the column was eluted with 85% aqueous MeOH to afford M3 (4 mg) and a mixture of M1 and M2 (60 mg). The mixture of M1 and M2 was further applied to a column (3 cmϫ40 cm) of silica gel and the column was eluted with hexane-ethyl acetate (7 : 3→1 : 1) to afford M1 (12 mg) and M2 (16 mg).
Cell Culture DLD-1 (JCRB9094) and WiDr (IFO50043) human colorectal adenocarcinoma cells were purchased from Health Science Research Resources Bank (Osaka, Japan). CACO-2 (RCB0988) and Colo-320 (RCB1193) human colon carcinoma cells were provided by RIKEN Cell Bank (Tsukuba, Japan). DLD-1 and Colo-320 cells were maintained in RPMI1640 medium (Sigma). CACO-2 and WiDr cells were maintained in minimal essential medium (MEM; Sigma). Cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 in air in medium supplemented with 10% or 20% heat-inactivated fetal bovine serum (JRH bioscience, U.S.A.), penicillin (5000 IU/ml), and streptomycin (5000 mg/ml) (ICN Biomedicals, Inc., Ohio, U.S.A.).
Measurement of EPO and Its Metabolites on Cell Viability EPO and its metabolites were dissolved in dimethyl sulfoxide (DMSO) and added to the cell culture media (final DMSO concentration was 0.5%). CACO-2, DLD-1, Colo-320 and WiDr cells were seeded at 2ϫ10 4 cells/ml on 96-well plates, incubated for 24 h to allow the cells to adhere to the bottom of the culture plates, and then treated with EPO or its metabolites for 48 h. The cell viability was determined using WST-1 reagent (Takara, Japan). The number of viable control cells was counted with a hemocytometer by a trypan blue exclusion method. Data are expressed as the meanϮ standard deviation (S.D.) of triplicate determinations. Cytotoxic activities against the human colorectal cancer cell lines were compared with those of 5-fluorouracil (99%, SigmaAldrich Inc., U.S.A.), which is used clinically for cancer patients. The purity of EPO and its metabolites for the bioassay was determined by LC/MS to be Ͼ98%. C-NMR spectra. Its physical and spectroscopic data were both in full agreement with those previously reported. 5, 16) Metabolism of EPO by RIB and Structural Determination of M1, M2 and M3 As shown in Fig. 1 , EPO was metabolized by RIB even after incubation for 32 h. EPO was transformed to M1-M3 by anaerobic incubation with rat intestinal flora. These metabolites were isolated and purified as described in Experimental. Positive-ion LC/MS showed that three major metabolites had the same [MϩH] ϩ ion with EPO at m/z 429. M1 was obtained as a colorless amorphous powder. (Table 3) . On the basis of the above evidence, the structure of M1 was determined as 5a,6a-epoxyergosta-8(14),22-diene-3b,7a-diol (2). The 1 H-and 13 C-NMR spectral data were in agreement with those reported. 8, 40) The spectral data of M2 were very similar to those of M1. The major difference was olefinic carbon signals at d 126.9 and 134.4 in the 13 C-NMR, indicating the presence of a double bond at C-8 and C-9, which was confirmed by 2D-NMRs. The structure of M2 was consequently determined as 5a,6a-epoxyergosta-8,22-diene-3b,7a-diol (3) by comparison of several spectral data with those in the literature. 8, 40) M3 was detected as the third metabolite of EPO by anaerobic incubation with a rat fecal suspension. It showed a dark yellow spot on the TLC plates after spraying with 10% H 2 SO 4 followed by heating. The spectral data of M3 were very similar to those of M1 and M2. However, the 13 C-NMR spectrum showed one carbonyl carbon signal at d 207.5, instead of oxygenated carbon signals of M1 and M2 corresponding to C-7. The HMBC correlation of a carbonyl carbon signal at d 207.5 with H-6 (d 3.04) and H-8 (d 1.93), and a methyl proton signal at d 1.03 (H-19) was long-range correlated to an epoxy carbon signal at d 68.1 (C-5), to which a proton signal at d 3.04 (H-6) was correlated. Furthermore, an axial methyl signal (H-19) gave NOESY correlations to H-4b, H-6b and H-8b, suggesting that the protons are the same axial configurations (Fig. 4) . Based on the above evidence, the structure of M3 was determined as 5a,6a-epoxy-3b-hydroxyergosta-22-ene-7-one (4). Validation of Metabolites from Rat Feces after p.o. Administration of EPO EPO (100 mg/kg) was administered via a gastric tube to male rats and fecal samples were collected in polyethylene tubes at intervals of 0-8, 8-16, and 16-24 h after p.o. administration. EPO and several metabolites were detected in the rat feces (Fig. 2) . The original EPO was eluted at 22.6 min. The fragmentation patterns of peaks at 17.6, 17.8 and 24.2 min were similar to that of EPO (Table  1) , and they were identified as M1, M2 and M3, respectively, by comparison of their retention times and MS with those of authentic samples. They were not detected in the normal rat feces.
RESULTS
Identification and Characterization of Ergosterol Peroxide
Cytotoxic Effect of EPO and Its Metabolites against CACO-2, WiDr, DLD-1 and Colo-320 Human Colorectal Adenocarcinoma Cells CACO-2, WiDr, DLD-1 and Colo-320 human colon carcinoma cells were treated with EPO and its metabolites for 2 d. These compounds showed an appreciably cytotoxic effect on the four colorectal adenocarcinoma cells at concentrations of 3.1-25 mg/ml. Of these, the cytotoxic effect of M2 and M3 on the tumor cell lines was at least twice as potent as that of EPO itself. Moreover, the cytotoxic effects of M2 and M3 were stronger than that of a positive control, 5-fluorouracil.
DISCUSSION
Ergosterol peroxide is known to be a major anti-tumor sterol present in medicinal mushrooms, lichens, sponges and some marine organisms. In the present study, EPO was demonstrated to be metabolized by rat intestinal flora to three major metabolites, M1, M2 and M3. Bergmann and Meyers reported that rearrangement of EPO could occur only when EPO was heated above its melting point to approximately 200°C in vitro to yield three isomers, 5a,6a-epoxyergosta-8(14),22-diene-3b,7a-diol (M1), 5a,6a-epoxyergosta-8,22-diene-3b,7a-diol (M2), and 5a,6a-epoxy-3b-hydroxyergosta-22-ene-7-one (M3). 39) An enzyme catalyzed rearrangement of EPO to the isomeric epoxydiols has been described for 12 bacterial strains, mainly species of the genera Mycobacterium and Nocardia. 40) In contrast with the bacteria, the rearrangement by EPO isomerase in Saccharomyces cerevisiae gave almost exclusively 5a,6a-epoxyergosta-8,22-diene-3b,7a-diol (M2). 41 ) Therefore, we believe that the presence of an EPO isomerase and/or nonspecific enzymes that originated from intestinal bacteria played important roles in the transforming processes.
In addition, we compared the proliferation inhibitory activity of the metabolites against four colorectal cancer cell lines with that of EPO. Interestingly, the metabolites of EPO (4) produced by intestinal bacteria exhibited more potent cytostatic activity than EPO itself (Table 4) .
The large intestine contains a complex and dynamic microbial ecosystem with high densities of living bacteria, which achieve concentrations of up to 10 11 or 10 12 cells/g of luminal contents. A large proportion of the fecal mass consists of bacteria (around 60% of fecal solid). The composition of human intestinal bacteria and that of rat intestinal bacteria are quite different. The genera bacteroids, Actinobacillus, Streptococcus, anaerobic curved rods, Bacteroides, Fusobacterium, Lactobacillus, Propionibacterium, Eubacterium, Peptococcus and Bifidobacterium are predominant in rats. In contrast, the genera bacteroids, Bifidobacterium, Eubacterium, Clostridium, Peptococcus, Peptostreptococcus, and Ruminococcus are predominant in humans, whereas aerobes (facultative anaerobes) such as Escherichia, Enterobacter, Enterococcus, Klebsiella, Lactobacillus, and Proteus are among the subdominant gerera. 42) We also tested human intestinal bacteria (HIB) in the transformation of EPO to M1-M3, and obtained exactly the same results as that of rat intestinal bacteria (RIB), regardless of the difference in bacterial species between rats and humans (data not shown).
Since we also detected the same metabolites of EPO produced by human intestinal bacteria, it is significant that EPO can be transformed into more potent anti-colon cancer compounds only in situ by intestinal bacteria. The results suggest that intestinal bacteria play important roles in the transformation-activation of EPO. Several researchers have reported that EPO had more cytotoxic activity than ergosterol, and the activity was probably due to the presence of a peroxide group.
13) The present result that EPO metabolites without a peroxide bond showed more potent activity may suggest the epoxide group is another important pharmacophore for the cytotoxic activity.
To the best of our knowledge, this is the first report on the biotransformation of EPO by intestinal bacteria and on biological activity. The mechanism on the cytotoxic activity of the metabolites is not well understood at present. Therefore, it is necessary to clarify the mechanism of action of the inhibition of cell proliferation of the metabolites. 
